EUVIMEDEUVIMED entdecken
Multizentrische Studie

Why do people still make anti‐D over 50 years after the introduction of Rho(D) immune globulin? A Biomedical Excellence for Safer Transfusion (BEST) Collaborative study

Regina M DelBaugh, Michael F Murphy iD, Julie Staves, Roberta Maria Fachini, Silvano Wendel iD, Katie Hands, Carolina Bonet-Bub iD, Jose Mauro Kutner, Claudia S Cohn iD, Cody A Cox, Cyril Jacquot iD, Rida A Hasan iD und 11 weitere

Transfusion · 2025

DOI: 10.1111/trf.18202 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Transfusion, 2025. Verfasst von Regina M DelBaugh und 22 weiteren Autor:innen. Beteiligte Einrichtung: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA. Hauptthemen laut MEDLINE: Rho(D) Immune Globulin, Isoantibodies, Rh Isoimmunization, Rh-Hr Blood-Group System. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rho(D) immune globulin (RhIg) is used to reduce RhD alloimmunization in pregnancy. This study describes potential causes for RhD alloimmunization after the development and implementation of RhIg. Study Design and Methods This retrospective descriptive study investigated RhD‐negative patients born in 1965–2005 with anti‐D newly identified during 2018–2022. Transfusion, pregnancy, intravenous drug abuse, and transplantation were considered potential alloimmunization sources.

Results

There were 1200 study patients (852 females; 348 males) at 30 institutions in 5 countries (USA, Canada, UK, New Zealand, Brazil). Most patients had a single potential source of alloimmunization identified (857/1200, 71%), most commonly pregnancy among females (537/852, 63%) and transfusion among males (180/348, 52%). When multiple potential sources were included, males were more likely than females to have a history of transfusion (235/348 [68%] vs. 149/852 [17%], p < .0001) and confirmed or suspected intravenous drug abuse (100/348 [29%] vs. 138/852 [16%], p < .0001). Among females with a history of pregnancy, 119/718 (17%) had healthcare access issues, 120/718 (17%) had pregnancy in a country where they may not have received RhIg, and 21/718 (3%) refused RhIg. Among patients with a history of transfusion, males were more likely than females to have received RhD‐positive red blood cells or whole blood (143/235 [61%] vs. 30/149 [20%], p < .0001) and/or platelets (84/235 [36%] vs. 19/149 [13%], p < .0001).

Discussion

Pregnancy was the most frequently identified potential source of RhD alloimmunization among females. Transfusion was most frequent in males. Intravenous drug abuse as a common potential source among patients with RhD alloimmunization merits further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rho(D) Immune GlobulinIsoantibodiesRh IsoimmunizationRh-Hr Blood-Group SystemHumansFemaleMaleRetrospective StudiesPregnancyAdultBlood TransfusionMiddle Aged

Stichwörter der Autor:innen

Rho(D) immune globulin (RhIg)alloimmunizationanti‐Dintravenous drug abusepregnancytransfusiontransplant

Substanzen

Rho(D) Immune GlobulinIsoantibodiesRh-Hr Blood-Group System

Autor:innen und Institutionen

  • Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.
  • Oxford University Hospitals, Oxford, UK.
  • Hospital Sírio-Libanês, São Paulo, Brazil.
  • Scottish National Blood Transfusion Service, Ninewells Hospital, Dundee, UK.
  • Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • M-Health Fairview, Minneapolis, Minnesota, USA.

ORCID-Profile: Michael F Murphy, Silvano Wendel, Carolina Bonet-Bub, Claudia S Cohn, Cyril Jacquot, Rida A Hasan, Wen Lu, Justin E Juskewitch, Jay S Raval, Mark K Fung, Alyssa Ziman, Nancy M Dunbar

Zitieren

APA

DelBaugh, R. M., Murphy, M. F., Staves, J., Fachini, R. M., Wendel, S., Hands, K., Bonet-Bub, C., Kutner, J. M., Cohn, C. S., Cox, C. A., Jacquot, C., Hasan, R. A., Lu, W., Juskewitch, J. E., Raval, J. S., Rollins-Raval, M. A., Fung, M. K., Ziman, A., Fermon, E. J., …, & BEST foRmation of Anti‐D After Rhogam (RADAR) Study Investigators and the Biomedical Excellence for Safer Transfusion (BEST) Collaborative (2025). Why do people still make anti‐D over 50 years after the introduction of Rho(D) immune globulin? A Biomedical Excellence for Safer Transfusion (BEST) Collaborative study. Transfusion. https://doi.org/10.1111/trf.18202

Vancouver

DelBaugh RM, Murphy MF, Staves J, Fachini RM, Wendel S, Hands K, et al. Why do people still make anti‐D over 50 years after the introduction of Rho(D) immune globulin? A Biomedical Excellence for Safer Transfusion (BEST) Collaborative study. Transfusion. 2025. doi:10.1111/trf.18202

BibTeX
@article{DelBaugh2025,
  author = {DelBaugh, Regina M and Murphy, Michael F and Staves, Julie and Fachini, Roberta Maria and Wendel, Silvano and Hands, Katie and Bonet-Bub, Carolina and Kutner, Jose Mauro and Cohn, Claudia S and Cox, Cody A and Jacquot, Cyril and Hasan, Rida A and Lu, Wen and Juskewitch, Justin E and Raval, Jay S and Rollins-Raval, Marian A and Fung, Mark K and Ziman, Alyssa and Fermon, Erica J and Gorlin, Jed B and Peters, Jessica and Dunbar, Nancy M and BEST foRmation of Anti‐D After Rhogam (RADAR) Study Investigators and the Biomedical Excellence for Safer Transfusion (BEST) Collaborative, BEST foRmation of Anti‐D After Rhogam (RADAR) Study Investigators and the Biomedical Excellence for Safer Transfusion (BEST) Collaborative},
  title = {Why do people still make anti‐D over 50 years after the introduction of Rho(D) immune globulin? A Biomedical Excellence for Safer Transfusion (BEST) Collaborative study},
  journal = {Transfusion},
  year = {2025},
  doi = {10.1111/trf.18202}
}
Kostenlos starten →